Vas Narasimhan, Novartis CEO (Jason Alden/Bloomberg via Getty Images)
August 25, 2022 04:55 AM EDTUpdated 07:20 AM
Deals

Af­ter wrestling with the San­doz prob­lem for sev­er­al years, Vas Narasimhan set­tles on a spin­out

John Carroll

Editor & Founder

No­var­tis CEO Vas Narasimhan has fi­nal­ly fig­ured out how he can get San­doz off his list of ma­jor headaches. He’s go­ing to spin the gener­ics …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sanofi's BTK in­hibitor again slows MS pro­gres­sion, but liv­er en­zymes con­tin­ue to be tricky

Lex­i­con's pres­i­dent to step down as de­ci­sion date looms; Sarep­ta wel­comes Lil­ly, GSK vet to board

Gilead­'s Kite un­cou­ples from Fo­s­un in Chi­na as Yescar­ta faces cov­er­age ob­sta­cles

Ali­gos’ tri­al for oral MASH treat­ment suc­ceeds, but place­bo group shows odd trend

FDA in­spec­tors dis­cov­er trucks car­ry­ing torn-up records leav­ing In­di­an gener­ics fac­to­ry

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times